The interaction between CD40 ligand (CD40L) and CD40 on antigen-presenting cells is essential for the initiation of antigenspecific T-cell responses. In order to clarify whether the expression of CD40L in tumor cells might be useful as a systemic therapy against bladder cancer, we investigated the antitumor immunity induced by CD40L in the mouse bladder cancer cell line MBT2. MBT2 was transduced by the retroviral vector expressing CD40L (MBT2-CD40L). Mouse bone marrow-derived dendritic cells cocultured with MBT2-CD40L cells produced eight times more IL-12 than those cocultured with parental MBT2 cells. In animal studies, subcutaneously inoculated MBT2-CD40L cells were rejected promptly. The vaccination of MBT2-CD40L cells induced antitumor immunity against parental tumors at a distant site. However, the antitumor effect of MBT2-CD40L inoculation was insufficient against pre-existing tumors. In the vaccination model, antibody ablation studies revealed that CD4 + T cells were required for antitumor immunity, and tumor-specific cytotoxicity of sera was demonstrated. These data demonstrated that the antitumor immunity induced by CD40L was effective in the vaccination model and suggested that immunogene therapy using CD40L may be a new strategy of systemic therapy against bladder cancer. Cancer Gene Therapy (2003) 10, 833-839. doi:10.1038/sj.cgt.7700627
T he application of a new systemic therapy for advanced bladder cancer is one of the most important issues in genitourinary cancer because systemic chemotherapy has only a very limited effect in these cases. The application of immunotherapy using recombinant murine IL-12 (rmIL-12) in a mouse bladder cancer model was reported in a previous study. 1 This study demonstrated that the intraperitoneal (i.p.) injection of rmIL-12 induced antitumor immunity against subcutaneously (s.c.) inoculated bladder cancer. This antitumor effect, however, was limited. Recently, an immunogene therapy strategy involving the induction of antitumor immunity by genetically modifying tumor cells with CD40L cDNA was demonstrated in several cancer models. [2] [3] [4] The CD40 ligand (CD40L) is a 33-kDa type II membrane protein belonging to the tumor necrosis factor (TNF) family and is predominantly expressed on CD4 + T cells upon T-cell receptor (TCR) stimulation. Its receptor, CD40, belongs to the TNF receptor family and is expressed on B cells, macrophages and dendritic cells (DCs). 5 The interaction between CD40L and CD40 on antigen-presenting cells (APCs) activates the APCs, and this interaction is essential for the initiation of antigenspecific T-cell responses. 6 The CD40L on antigen-stimulated CD4 + T cells activates the APCs, with upregulation of the B7 family of T-cell costimulatory molecules and consequent direct stimulation of CD8 + T cells. 7 In addition, the activated APCs produce proinflammatory cytokines such as IL-12. [8] [9] [10] Recent reports have demonstrated that the expression of CD40L in several cancer models reduced their tumorigenicity and elicited protective immunity. [2] [3] [4] These observations suggest that tumor cells expressing CD40L activate APCs by CD40L-CD40 interaction and induce a CD8 + T-cell-mediated protective immunity against tumor cells. The mechanisms of the antitumor immunity induced by CD40L, however, have not been elucidated sufficiently in vivo.
Therefore, we investigated the antitumor immunity induced by the expression of CD40L in MBT-2 mouse bladder cancer cells in vitro and vivo, in order to clarify whether the expression of CD40L in tumor cells can be useful as part of a new strategy of systemic therapy against bladder cancer.
Materials and methods

Mice
Female C3H/He mice, 6-to 8 weeks old, purchased from Shizuoka Laboratory (Shizuoka, Japan), and severe combined immunodeficiency (SCID) mice, purchased from Sankyo (Tokyo, Japan) were maintained in a specific pathogen-free room at 25731C and treated according to National Institutes of Health guidelines. The ethical issues related to this study were discussed and approved by the intramural ethical committee.
Cell lines and transduction
MBT2, a mouse bladder carcinoma cell line (provided by Dr I Hara, Kobe University), and MIH2, a mouse hepatocellular carcinoma cell line (provided by Dr M Irie, Jikei University School of Medicine), are of C3H/He origin. In order to generate the retroviral vector, mouse CD40L cDNA (provided by Dr H Yagita, Juntendo University, School of Medicine) was linker-ligated into the EcoRI sites of the retroviral vector pMND-X-SN 11 (provided by Dr DB Kohn, University of Southern California School of Medicine) (pMND-mCD40L-SN). The retroviral vector (MND-mCD40L-SN) was generated using the packaging cell lines Bosc23 12 and ccrip. 13 The MBT2 was transduced with this retroviral vector, and a stable clone was isolated by G418 (Sigma, St Louis, MO) selection (MBT2-CD40L). The clone with the highest expression of CD40L was chosen and expanded, and these cells were used for further experiments. The mock MBT2 (MBT2-MOCK) was generated similarly and infected with the same retrovirus vector, but without the insert.
RT-PCR
To assay the expression of CD40L in the transfected cell line, total cellular RNA was extracted from the tumor cells using an RNeasy s kit (Qiagen, Inc., Valencia, CA). RT-PCR was performed for CD40L and b-actin using RNA PCR TM Kit (AMV) Ver.2.1 (TaKaRa, Kyoto, Japan) following the manufacturer's instructions. The specific primers for CD40L and b-actin were 5 0 -ATGA-TAGAAACATACAGCCAACCT-3 0 5 0 -TCAGAGTTT-GATGAAGCCAAAAGA-3 0 and 5 0 -GACTACCTCAT-GAAGATCCT-3 0 5 0 -GCGGATGTCCACGTCACACT-3 0 , respectively. For both CD40L and b-actin, the PCR condition was one cycle at 941C for 2 minutes; 35 cycles at 941C for 1 minute, 551C for 1 minute, and 681C for 1 minute; followed by one cycle at 681C for 7 minutes. The PCR products were run on a 2% agarose gel and visualized by ethidium bromide staining.
Flow cytometry
The expression of CD40 and CD40L on transfected and parental cell lines was examined using flow cytometry. 14 Briefly, single-cell suspensions of the cells were washed, resuspended in buffer (1% BSA, 0.1% sodium azide in PBS) and reacted with FITC-conjugate anti-mouse CD40 MAb (monoclonal antibody) or PE-conjugate antimouse CD40L MAb (PharMingen, San Diego, CA) for 30 minutes at 41C. The stained cells were washed with buffer and analyzed using a FACScan flow cytometer (Becton Dickinson, San Jose, CA).
Ability to activate DCs by CD40L expression
To investigate the ability of MBT2-CD40L cells to activate DCs, mouse bone marrow-derived dendritic cells (BMDCs 1.5 Â 10 5 cells/well) were cocultured with MBT2, MBT2-MOCK or MBT2-CD40L cells (1 Â 10 5 cells/ well). The BMDCs were grown as previously described. 15 The MBT2, MBT2-MOCK and MBT2-CD40L cells were irradiated with 50 Gy (Hitachi MBR-1520, dose rate: 1.1 Gy/minute). As a control, BMDCs were cultivated without the addition of any other cells. After incubation for 24 hours, the level of mouse IL-12 released into the culture medium was determined by enzyme-linked immunosorbent assay (ELISA), using an OptEIAt Mouse IL-12 p40 set (PharMingen, San Diego, CA) according to the manufacturer's instructions. All determinations were made in triplicate. 
Animal models
. Each group consisted of at least five mice, and the experiment was repeated three times.
Assay of cytolytic activity
To investigate the ability of MBT2-CD40L cells to induce tumor-specific cytotoxic T lymphocytes (CTLs) in the vaccination model, the cytolytic activity of activated spleen cells (SPCs) was tested in vitro in a standard 51 Crrelease assay. 16 Single-cell suspensions of SPCs obtained from mice inoculated with irradiated MBT2-CD40L cells or PBS twice were prepared. These SPCs were washed and resuspended in 10% FCS/RPMI medium at a concentration of 1 Â 10 8 /ml in six-well dishes. After the removal of adherent cells, 50 U/ml of recombinant human IL-2 (rhIL-2; provided by Shionogi, Osaka, Japan) was added to the cultures every other day. MBT2 cells were irradiated with 200 Gy and added to the culture at a concentration of 1 Â 10 5 /ml. At 5 days after culture initiation, cells were harvested, and CTL activity was determined. MBT2 were used as the target cells. The target cells were labeled by incubation with 51 Cr for 90 minutes at 371C and then cocultured with effector Antitumor effect induced by CD40L against bladder cancer T Kimura et al lymphocytes for 4 hours. The effector: target ratio ranged from 5:1 to 80:1. All determinations were made in triplicate, and the percentage of lysis was calculated using the following formula: experimental cpm À spontaneous cpm maximum cpm À spontaneous cpm Â 100%
Antibody ablation studies
In the vaccination model, the rat MAbs anti-mCD4 (ATCC hybridoma GK 1.5), anti-mCD8 (ATCC hybridoma 56.6.73), anti-asialo GM1 (Wako, Tokyo, Japan) or normal rat IgG was purified from ascites and injected i.p.
(0.5 mg/injection/mouse) on days -4, -1, 4 and 8 relative to parental tumor inoculation (day 0). 14 Irradiated MBT2-CD40L cells or PBS as control were inoculated s.c. on days -14 and -7. To monitor for the desired ablation of lymphocyte subsets, the expression of CD4, CD8 and asialoGM in splenocytes was analyzed by flow cytometry. Each group consisted of at least five mice, and the experiment was repeated three times.
Detection of tumor cell-binding Ig in sera
Detection of tumor cell-binding immunoglobulin (Ig) in sera was described. 17 Briefly, 25 ml of sera obtained from mice inoculated with irradiated MBT2, MBT2-CD40L cells or PBS twice was added to 4 Â 10 5 single-cell suspensions of MBT2 cells. The cells were incubated for 30 minutes at 41C, washed, resuspended in buffer (1% BSA, 0.1% sodium azide in PBS) and stained with FITClabeled anti-mouse IgG MAb (PharMingen, San Diego, CA) for 30 minutes at 41C. The stained cells were washed and analyzed using a FACScan flow cytometer.
Cytotoxicity of sera obtained from vaccinated mice in vitro
Cytotoxicity of sera obtained from vaccinated mice against MBT2 cells in vitro was detected by a modification of the method of Fujieda et al. 18 MBT2 cells (1 Â 10 5 ) in 96-well plates were incubated with 100 ml of culture medium as control or sera obtained from mice inoculated with irradiated MBT2, MBT2-CD40L cells or PBS twice (diluted 1:10 in culture medium) for 72 hours at 371C. Subsequently, 10 ml of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT) (5 mg/ml) (Sigma Chemical Co., St Louis, MO) was added to each well. After 4 hours of incubation, the medium was removed and the converted dye was solubilized with 0.1 N HCl in absolute isopropanol. Absorbance of converted dye was measured at a wavelength of 570 nm with background subtraction at 630 nm using microplate reader. MIH2 cells were used as a control of target cells. All determinations were made in triplicate. The cytotoxicity against target cells was calculated as follows: cytotoxic activity (%) ¼ 100(1ÀS/M), where S is the absorbance of the sample and M is the mean absorbance of triplicate wells with target cells in culture medium without sera.
Data analysis
The levels of IL-12 produced by BMDCs cocultured with tumor cells were compared using the Scheffe test. The calculated tumor sizes were compared using Student's ttest. CTL activities and cytotoxicity of sera in vitro were compared using Student's t-test. Differences were considered significant when the P-value was less than 0.05.
Results
Expression of CD40L in transfected cell line
Parental MBT2 cells expressed neither CD40 nor CD40L (Fig 1a,b) , whereas transfected MBT2-CD40L cells expressed CD40L (Fig 1c) . This was confirmed by RT-PCR (Fig 1d) . We studied the ability of MBT2-CD40L cells to activate DCs by monitoring IL-12 production by DCs cocultured with MBT2, MBT2-MOCK or MBT2-CD40L cells (Fig 2) . When the DCs were cocultured with MBT2 or MBT2-MOCK cells, the production of IL-12 by the DCs was reduced. However, when the DCs were cocultured with MBT2-CD40L cells, the IL-12 concentration in the medium was at least eight times higher than that obtained upon MBT2 or MBT2-MOCK cocultivation (Po0.001). These observations demonstrated that the MBT2-CD40L cells were able to activate DCs.
Antitumor effect of transduction of CD40L in vivo
We examined whether or not tumorigenicity differs between parental and CD40L transfected cells. The MBT2, MBT2-MOCK and MBT2-CD40L cells were inoculated into SCID mice. There were no remarkable differences in tumorgenicity among them (data not shown), suggesting that the transduction of CD40L molecules into MBT2 cells did not influence tumorgenicity. The MBT2 and MBT2-MOCK cells inoculated into the C3H/He mice grew gradually during the study period. However, the MBT2-CD40L cells were completely rejected, and no tumor growth was found during the study period (Fig 3) . In the vaccination model, even though the growth inhibition of MBT2 cells was investigated in mice vaccinated with MBT2, it was very limited and not significant statistically. Compared with this, vaccination of MBT2-CD40L enhanced the growth inhibition of MBT2 cells significantly (Po0.05) (Fig 4) . This means that expression of CD40L induced systemic antitumor immunity against MBT2 in this model. On the other hand, in the therapeutic model, none of the groups showed any significant difference in tumor growth. This means that the inoculation of MBT2-CD40L cells had no significant effect in this model (Fig 5) . Moreover, no antitumor effect was observed even when we administered IL-12 in order to produce a synergistic effect.
CTL assay
In various cell mixture ratios (splenocyte cell number: MBT2 cell number), there was no release of 51 Cr into the Antitumor effect induced by CD40L against bladder cancer T Kimura et al medium (data not shown), suggesting that there was no CTL activation in the vaccination model.
Antibody ablation studies
To elucidate effector cell functions in the vaccination model, the lymphocyte ablation study was performed. Lymphocyte subsets were depleted by administering anti-CD4, anti-CD8, anti-asialo GM1 or control rat IgG into mice inoculated with MBT2-CD40L cells. First, to confirm that the desired ablation of lymphocyte subsets was achieved, their splenocytes were analyzed by flow cytometry using various specific antibodies for lympho- Antitumor effect induced by CD40L against bladder cancer T Kimura et al cyte lineage. We confirmed the successful depletion of each T-cell subpopulation of SPCs from the mice on day 10 and on day 21 (data not shown). The antitumor effect was significantly reduced in mice depleted of CD4 + T cells compared with mice inoculated with control rat IgG (Po.05) (Fig 6) . These results demonstrated that CD4 + T cells were required for the antitumor effect induced by CD40L, and CD8 + T and NK cells did not play an important role in the vaccination model.
Antitumor effect induced by humoral immunity
We examined whether or not humoral immunity plays an important role for the antitumor effect in the vaccination model. Initially, we examined tumor cell-binding Ig in sera obtained from vaccinated mice. Tumor cell-binding Ig was detected in mice vaccinated with both MBT2 and MBT2-CD40L cells (Fig 7) . Next, we examined direct cytotoxicity of sera obtained from vaccinated mice in vitro. The cytotoxicity of sera obtained from mice vaccinated with MBT2-CD40L was significantly stronger than that obtained from mice vaccinated with either MBT2 or PBS (Po0.05) in vitro, and this effect was specific (Fig 8) . These results suggest that the humoral immunity may play a role for the antitumor effect in the vaccination model.
Discussion
The immunogene therapy strategy using genetically modified tumor cells expressing CD40L-induced antitumor immunity has been demonstrated in several cancer models.
2-4 Nakajima et al. 3 demonstrated in a P815 mastocytoma model that the vaccination of tumor cells expressing CD40L elicited CD8 + T-cell-mediated protective and systemic immunity against parental tumor cells. They concluded that the host APC was stimulated by CD40L to upregulate B7 and activate CD4 + T cells, which in turn helped the development of CD8 + T cells. Kikuchi and Crystal 4 reported that intratumoral injection of adenovirus vector expressing CD40L suppressed the growth of established tumor cells and that ex vivo Antitumor effect induced by CD40L against bladder cancer T Kimura et al transduction of tumor cells to express CD40L induced systemic antitumor immunity in a CT26 colon cancer model. They also demonstrated that in vivo and in vitro modification of tumor cells to express CD40L elicited tumor-specific CTL activity. 4 In contrast, the present study in a bladder cancer model demonstrated that vaccination of MBT2 cells expressing CD40L did not induce tumor-specific CTL activity and that systemic immunity against parental tumor cells required CD4 + T cells and not CD8 + T cells. Tumor cell-binding Ig was detected in sera obtained from mice vaccinated with MBT2-CD40L cells and the sera had specific cytotoxicity against parental MBT2 cells in vitro. In addition, i.p. administration of sera obtained from mice vaccinated with MBT2-CD40L showed a tendency to inhibit the growth of MBT2 cells more than that obtained from mice vaccinated with MBT2 or PBS even though there was no statistically, significant difference and the effect was limited (data not shown). These results suggest the possibility that the humoral immunity may participate in the antitumor effect in this model. As MBT2 expressed not MHC class I but MHC class II molecules (data not shown), the participation of the host APCs is required for the induction of humoral immunity against MBT2. We found that MBT2-CD40L cells activated DCs in vitro. Although it is not indicated directly, these results suggest a scenario in which MBT2-CD40L cells activate DCs by CD40L-CD40 interaction, and the activated DCs then present tumor antigen and stimulate CD4 + T cells. Consequently, the CD4 + T cells may induce antitumor humoral immunity. Otherwise, a third mechanism other than the humoral immunity may be involved in this antitumor effect. There is a possibility that the mechanism of the antitumor immunity induced by CD40L in vivo differs depending on the immunological characters of the various tumor cells. As already demonstrated, vaccination of SRB10A, mouse glioma cell line, modified to express CD40L, inhibited the growth of parental tumor cells, and CTL activity was investigated in this model (unpublished observation).
In 2001, during the preparation of this manuscript, another report concerning antitumor immunity induced by CD40L in a bladder cancer model was published by Loskog et al. 19 There are several discrepancies between their report and ours. In their report, another mouse bladder cancer cell line, MB-49, transduced with adenovirus vector expressing CD40L, induced antitumor immunity, and immunohistochemistry revealed that tumors expressing CD40L were infiltrated with large numbers of CD4 + and CD8 + T cells. We could not observe any infiltration of lymphocytes into inoculated MBT2 cells expressing CD40L (data not shown). In addition, the immunological character of MB-49 cells is different from that of MBT2. MB-49 cells expressed CD40, but MBT2 did not. These immunological differences might be influencing the mechanisms involved in antitumor immunity.
Although antitumor immunity induced by CD40L was significant in preventing tumor growth in the vaccination model, it was insufficient against pre-existing tumors. In addition, the synergistic antitumor effect of CD40L and IL-12 was not demonstrated. However, this study indicates that immunogene therapy using CD40L might be a new strategy of systemic therapy against bladder cancer. Further studies, such as those on enhancing the antitumor effect on pre-existing tumors, are currently underway. 
Conclusions
This study demonstrated that antitumor immunity induced by the ex vivo retrovirus vector-mediated expression of CD40L is effective in a vaccination model. This antitumor effect might require CD4 + T cell, and humoral immunity might play a role in this model. Immunogene therapy using CD40L might be a new strategy of systemic therapy against bladder cancer. Figure 8 Cytotoxicity of sera obtained from vaccinated mice against MBT2 in vitro. Target cells were incubated with culture medium or sera, obtained from mice inoculated with irradiated MBT2, MBT2-CD40L or PBS, for 72 hours and MTT assay was examined. All determinations were made in triplicate. The cytotoxicity against target cells was calculated as follows: cytotoxic activity (%) ¼ 100(1ÀS/M), where S is the absorbance of the sample and M is the mean absorbance of triplicate wells with target cells in culture medium without sera. The cytotoxicity of sera obtained from mice vaccinated with MBT2-CD40L against MBT2 was significantly stronger than that obtained from mice vaccinated with either MBT2 or PBS (Student's t-test; Po0.05) (a), and this effect was not detected against MIH2 (b).
